{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:216210",
      "entity_text" : "dabigatran",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11626560",
      "entity_text" : "crizotinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_F568" ],
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0665" ]
    }
  },
  "verbose_text" : "There was concern regarding a potential interaction between crizotinib and dabigatran as the former has been shown to act as an inhibitor of P-glycoprotein and the latter is a P-glycoprotein substrate.1, 2 The theoretical risk of increased dabigatran levels was not observed : levels were measured by calibrated diluted thrombin assay (Hyphen (R)) on multiple occasions 90 minutes postadministration of dabigatran, but no detectable dabigatran was demonstrated.",
  "reading_complete" : "2020-08-03T12:46:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T12:45:02Z",
  "trigger" : "interaction",
  "evidence" : [ "interaction between crizotinib and dabigatran" ],
  "pmc_id" : "6510014",
  "score" : 0
}